| (Values in U.S. Thousands) | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 | Dec, 2020 |
| Sales | 310 | 310 | 230 | 20,380 | 0 |
| Sales Growth | unch | +34.78% | -98.87% | unch | unch |
| Net Income | -149,270 | -40,220 | -152,390 | -167,810 | -169,840 |
| Net Income Growth | -271.13% | +73.61% | +9.19% | +1.20% | -1,101.13% |
Ataibeckley Inc
(ATAI)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
AtaiBeckley Inc. is a clinical-stage biopharmaceutical company developing mental health treatments. The company's pipeline of novel therapies includes BPL-003 for treatment-resistant depression, VLS-01 for TRD and EMP-01 for social anxiety disorder. AtaiBeckley Inc., formerly known as Atai Beckley N.V., is based in NEW YORK.
Fiscal Year End Date: 12/31